未登录.png)
分享.png)
收藏Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trialSacituzumab tirumotecan在既往治疗过的转移性三阴性乳腺癌中的疗效：一项随机III期临床试验
Yin, Yongmei; Fan, Ying; Ouyang, Quchang; Song, Lihua; Wang, Xiaojia; Li, Wei; Li, Man; Yan, Xi; Wang, Shusen; Sun, Tao; Teng, Yuee; Tang, Xianjun; Tong, Zhongsheng; Sun, Zhengkui; Ge, Junyou; Jin, Xiaoping; Diao, Yina; Liu, Gesha; Xu, Binghe 分享 收藏 Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trialPyrotinib和曲妥珠单抗联合治疗协同克服HER2-positive乳腺癌的HER2依赖性: 来自PHILA试验的见解Liu, Shuning; Lan, Bo; Wang, Yuanyi; Yang, Tao; Li, Lixi; Ge, Hewei; Zeng, Cheng; Xu, Binghe; Qian, Haili; Ma, Fei 分享 收藏 分享 收藏 Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trialXu, Binghe; Wang, Shusen; Yan, Min; Sohn, Joohyuk; Li, Wei; Tang, Jinhai; Wang, Xiaojia; Wang, Ying; Im, Seock-Ah; Jiang, Dongdong; Valdez, Theresa; Dasgupta, Anandaroop; Zhang, Yiran; Yan, Yilin; Komatsubara, Kimberly M.; Chung, Wei-Pang; Ma, Fei; Dai, Ming-Shen 分享 收藏 Dato-DXd vs. chemotherapy for patients with inoperable/ metastatic HR+/HER2L breast cancer: TROPION-Breast01 Asian subsetTsurutani, J.; Hattori, M.; Im, S.; Wang, S.; Lu, Y.; Sohn, J.; Zhang, Q.; Park, Y.; Lee, K.; Ozaki, Y.; Jiang, Z.; Chung, W.; De Laurentiis, M.; Pernas, S.; Xu, L.; Khan, S.; Denduluri, N.; Pistilli, B.; Bardia, A.; Xu, B. 分享 收藏 Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2-advanced breast cancerCDK4/6抑制剂交叉治疗的临床益处和安全性: HR /HER2-advanced乳腺癌的回顾性研究Zhao, Qi; Jiang, Mingxia; Liu, Jiaxuan; Zhang, Mengqi; He, Maiyue; Zhou, Shihan; Wang, Jiani; Mo, Hongnan; Lan, Bo; Yuan, Peng; Zhang, Pin; Ma, Fei; Li, Qiao; Xu, Binghe 分享 收藏 Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center studyJiang, Mingxia; Liu, Jiaxuan; He, Maiyue; Zhang, Mengqi; Zhou, Shihan; Chen, Shanshan; Cai, Ruigang; Mo, Hongnan; Lan, Bo; Zhang, Pin; Xu, Binghe; Li, Qiao 分享 收藏 分享 收藏 The feedback loop between MTA1 and MTA3/TRIM21 modulates stemness of breast cancer in response to estrogenMTA1和MTA3/TRIM21之间的反馈回路响应雌激素调节乳腺癌的stemnessZhang, Jingyao; Wang, Yinuo; Zhang, Jingjing; Wang, Xin; Liu, Jiaxiang; Huo, Miaomiao; Hu, Ting; Ma, Tianyu; Zhang, Die; Li, Yu; Guo, Chang; Yang, Yunkai; Zhang, Min; Yuan, Baowen; Qin, Hao; Teng, Xu; Gao, Tianyang; Hao, Xinhui; Yu, Hefen; Huang, Wei; Xu, Binghe; Wang, Yan 分享 收藏 Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysisJiang, Mingxia; Chai, Yue; Liu, Jiaxuan; He, Maiyue; Wang, Yipeng; Yang, Xue; Xing, Zeyu; Zhang, Mengqi; Zhou, Shihan; Ma, Fei; Wang, Jiayu; Yuan, Peng; Xu, Binghe; Li, Qiao 分享 收藏 Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trialMo, Hongnan; Yu, Yongpei; Sun, Xiaoying; Ge, Hewei; Yu, Lanlan; Guan, Xiuwen; Zhai, Jingtong; Zhu, Aihua; Wei, Yuhan; Wang, Jinjing; Yan, Xiaoyan; Qian, Haili; Xu, Binghe; Ma, Fei 分享 收藏 分享 收藏 分享 收藏 Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study在先前接受过治疗的HER2-low不可切除/转移性乳腺癌的亚洲患者中，曲妥珠单抗deruxtecan与医生选择的治疗: DESTINY-Breast04研究的亚组分析Yamashita, Toshinari; Sohn, Joo Hyuk; Tokunaga, Eriko; Niikura, Naoki; Park, Yeon Hee; Lee, Keun Seok; Chae, Yee Soo; Xu, Binghe; Wang, Xiaojia; Im, Seock-Ah; Li, Wei; Lu, Yen-Shen; Aguilar, Cecilia Orbegoso; Nishijima, Soichiro; Nishiyama, Yuji; Sugihara, Masahiro; Modi, Shanu; Tsurutani, Junji 分享 收藏 HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trialLi, Qiao; Cheng, Ying; Tong, Zhongsheng; Liu, Yunjiang; Wang, Xian; Yan, Min; Chang, Jianhua; Wang, Shusen; Du, Caiwen; Li, Liang; Wu, Chunjiao; Wang, Mingxia; Wang, Zhuo; Wu, Zhuli; Wang, Xingli; Jin, Yongli; Diao, Lei; Sun, Yi; Zhang, Yongjiao; Hui, Ai-Min; Xu, Binghe 分享 收藏 A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2-Breast Cancer Who Failed Standard of Care TherapiesXu, Binghe; Zhang, Pin; Sun, Tao; Wang, Ying; Tong, Zhongsheng; Phadke, Sneha; Feinstein, Trevor; Guo, Pengfei; Qu, Jing; Wang, Xiaoyu 分享 收藏 Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trialHortobagyi, Gabriel; Stroyakovsky, Daniil; Yardley, Denise; Huang, Chiun-Shen; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Parnizari, Federico; Ghaznawi, Farhat; Li, Zheng; Waters, Sorcha; Chakravartty, Arunava; Slamon, Dennis 分享 收藏 Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast CancerChai, Yue; Liu, Jiaxuan; Jiang, Mingxia; He, Maiyue; Wang, Xin; Wang, Yipeng; Yang, Xue; Wang, Jing; Xu, Binghe; Li, Qiao 分享 收藏 HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast CancerHurvitz, Sara; Loi, Sherene; O'Shaughnessy, Joyce; Okines, Alicia; Tolaney, Sara; Sohn, Joo Hyuk; Saura, Cristina; Zhu, Xiaofu; Cameron, David; Bachelot, Thomas; Hamilton, Erika; Curigliano, Giuseppe; Wolff, Antonio; Harbeck, Nadia; Masuda, Norikazu; Vahdat, Linda; Zaman, Khalil; Valdes-Albini, Frances; Block, Margaret; Pluard, Timothy; Tan, Tira; Gawryletz, Chelsea; Chan, Arlene; Bedard, Philippe; Yerushalmi, Rinat; Xu, Binghe; Tryfonidis, Konstantinos; Schmitt, Michael; Xie, Joan; Borges, Virginia 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI